Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

BACKGROUND: Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes resulting in constitutive activation of the mammalian target of rapamycin (mTOR). The drug sirolimus suppresses mTOR signaling. M...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bissler, John J., McCormack, Francis X., Young, Lisa R., Elwing, Jean M., Chuck, Gail, Leonard, Jennifer M., Schmithorst, Vincent J., Laor, Tal, Brody, Alan S., Bean, Judy, Salisbury, Shelia, Franz, David N.
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3398441/
https://ncbi.nlm.nih.gov/pubmed/18184959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa063564
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires